The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $103.78

Today's change+3.47 +3.46%
Updated December 2 4:02 PM EST. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $103.78

Today's change+3.47 +3.46%
Updated December 2 4:02 PM EST. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd crosses above 20-day moving average

Taro Pharmaceutical Industries Ltd closed up sharply Friday, rallying (U.S.)$3.47 or 3.46% to (U.S.)$103.78 and crossing above its 20-day moving average. Over the last five days, shares have lost 3.46% and are down 32.85% for the last year to date. This security has underperformed the S&P 500 by 31.46% during the last year.

Key company metrics

  • Open(U.S.) $100.64
  • Previous close(U.S.) $100.31
  • High(U.S.) $103.86
  • Low(U.S.) $99.67
  • Bid / Ask-- / --
  • YTD % change-32.85%
  • Volume181,520
  • Average volume (10-day)209,572
  • Average volume (1-month)257,676
  • Average volume (3-month)244,655
  • 52-week range(U.S.) $92.28 to (U.S.) $157.99
  • Beta0.81
  • Trailing P/E8.18×
  • P/E 1 year forward9.43×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $12.69
Updated December 2 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+54.59%

Based on its net profit margin of 54.59%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.17%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue229234265258
Total other revenue--------
Total revenue229234265258
Gross profit177183224214
Total cost of revenue51514144
Total operating expense87918385
Selling / general / administrative21222323
Research & development15182018
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income142143182173
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax160140138201
Income after tax124110115189
Income tax, total36302312
Net income124110115189
Total adjustments to net income--------
Net income before extra. items124110115189
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items124110115189
Inc. avail. to common incl. extra. items124110115189
Diluted net income124110115189
Dilution adjustment--------
Diluted weighted average shares41424343
Diluted EPS excluding extraordinary itemsvalue per share3.002.602.684.41
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.002.602.694.41